Prostate Health Index (PHI) as a triage tool for reducing unnecessary magnetic resonance imaging (MRI) in patients at risk of prostate cancer

IF 2.5 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinical biochemistry Pub Date : 2024-04-06 DOI:10.1016/j.clinbiochem.2024.110759

Luisa Agnello , Matteo Vidali , Giuseppe Salvaggio , Francesco Agnello , Bruna Lo Sasso , Caterina Maria Gambino , Marcello Ciaccio

{"title":"Prostate Health Index (PHI) as a triage tool for reducing unnecessary magnetic resonance imaging (MRI) in patients at risk of prostate cancer","authors":"Luisa Agnello , Matteo Vidali , Giuseppe Salvaggio , Francesco Agnello , Bruna Lo Sasso , Caterina Maria Gambino , Marcello Ciaccio","doi":"10.1016/j.clinbiochem.2024.110759","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>The aim of this study is to assess the usefulness of the Prostate Health Index (PHI) as a triage tool for selecting patients at risk of prostate cancer (PCa) who should undergo multiparametric Magnetic Resonance Imaging (mpMRI).</p></div><div><h3>Material and methods</h3><p>We enrolled 204 patients with suspected PCa. For each patient, a blood sample was collected before mpMRI to measure PHI. Findings on mpMRI were assessed according to the Prostate Imaging Reporting & Data System version 2.0 (PI-RADSv2) category scale.</p></div><div><h3>Results</h3><p>According to PI-RADSv2, patients were classified into two groups: PI-RADS < 3 (48 %) and ≥ 3 (52 %). PHI showed the best performance for predicting PI-RADS ≥ 3 [AUC: 0,747 (0,679–0,815), 0,680(0,607–0,754), and 0,613 (0,535–0,690) for PHI, PSA ratio, and total PSA, respectively]. The best PHI cut-off was 30, with a sensitivity of 90%.</p><p>At the univariate logistic regression, total PSA (p = 0.007), PSA ratio (p = 0.001), [-2]proPSA (p = 0.019) and PHI (p < 0.001) were associated with PI-RADS ≥ 3; however, at the multivariate analysis, only PHI (p < 0.001) was found to be an independent predictor of PI-RADS ≥ 3.</p></div><div><h3>Conclusion</h3><p>PHI could represent a reliable noninvasive tool for selecting patients to undergo mpMRI.</p></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"127 ","pages":"Article 110759"},"PeriodicalIF":2.5000,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical biochemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009912024000535","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

The aim of this study is to assess the usefulness of the Prostate Health Index (PHI) as a triage tool for selecting patients at risk of prostate cancer (PCa) who should undergo multiparametric Magnetic Resonance Imaging (mpMRI).

Material and methods

We enrolled 204 patients with suspected PCa. For each patient, a blood sample was collected before mpMRI to measure PHI. Findings on mpMRI were assessed according to the Prostate Imaging Reporting & Data System version 2.0 (PI-RADSv2) category scale.

Results

According to PI-RADSv2, patients were classified into two groups: PI-RADS < 3 (48 %) and ≥ 3 (52 %). PHI showed the best performance for predicting PI-RADS ≥ 3 [AUC: 0,747 (0,679–0,815), 0,680(0,607–0,754), and 0,613 (0,535–0,690) for PHI, PSA ratio, and total PSA, respectively]. The best PHI cut-off was 30, with a sensitivity of 90%.

At the univariate logistic regression, total PSA (p = 0.007), PSA ratio (p = 0.001), [-2]proPSA (p = 0.019) and PHI (p < 0.001) were associated with PI-RADS ≥ 3; however, at the multivariate analysis, only PHI (p < 0.001) was found to be an independent predictor of PI-RADS ≥ 3.

Conclusion

PHI could represent a reliable noninvasive tool for selecting patients to undergo mpMRI.

查看原文本刊更多论文

将前列腺健康指数（PHI）作为减少前列腺癌高危患者不必要磁共振成像（MRI）的分诊工具

导言：本研究旨在评估前列腺健康指数（PHI）作为分诊工具在选择应接受多参数磁共振成像（mpMRI）检查的前列腺癌（PCa）高危患者方面的实用性。在进行 mpMRI 检查前，我们为每位患者采集了血液样本，以测量 PHI。根据前列腺成像报告和数据系统 2.0 版（PI-RADSv2）分类表评估 mpMRI 的结果：PI-RADS <3（48%）和≥3（52%）。PHI 在预测 PI-RADS ≥ 3 方面表现最佳[AUC：PHI、PSA 比值和总 PSA 的 AUC 分别为 0,747 (0,679-0,815)、0,680(0,607-0,754) 和 0,613 (0,535-0,690)]。单变量逻辑回归结果显示，总 PSA（P = 0.007）、PSA 比值（P = 0.001）、[-2]proPSA（P = 0.019）和 PHI（P < 0.001）与 PI-RADS ≥ 3 相关；但在多变量分析中，发现只有 PHI（p < 0.001）是 PI-RADS ≥ 3 的独立预测因子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical biochemistry 医学-医学实验技术

CiteScore

5.10

自引率

0.00%

发文量

151

审稿时长

25 days

期刊介绍： Clinical Biochemistry publishes articles relating to clinical chemistry, molecular biology and genetics, therapeutic drug monitoring and toxicology, laboratory immunology and laboratory medicine in general, with the focus on analytical and clinical investigation of laboratory tests in humans used for diagnosis, prognosis, treatment and therapy, and monitoring of disease.